NCT00334139已完成4 期
A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 411
- 试验地点
- 1
- 主要终点
- Bone turnover assessed by bone turnover parameters
研究概览
简要总结
Bisphosphonates have been used extensively in the treatment and the prevention of skeletal complications associated with bone metastases in patients with breast cancer and prostate cancer.
The purpose of this study is to assess the effect of zoledronic acid patients with prostate cancer or breast cancer and bone metastasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
zoledronic acid
Experimental
干预措施: Zoledronic Acid (Drug)
结局指标
主要结局
Bone turnover assessed by bone turnover parameters
时间窗: every 30 days
次要结局
- Correlation between bone complications and bone turnover(end of study)
- Correlation between pain and bone turnover(at end of study)
- Quality of Life(every 30 days)
- Pain(every 30 days)
- Change in prostate specific antigen(every 30 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Efficacy and Safety on the Use of Bisphosphonates in PaediatricsBone FragileBisphosphonate-Associated OsteonecrosisChildrenAdverse EventsNCT04012320Centre Hospitalier Universitaire de Nīmes99
Unknown
2 期
Osteonecrosis of the Hip and Bisphosphonate TreatmentOsteonecrosisNCT00781261University of Sydney120
招募中
3 期
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric SurgeryBone LossNCT04922333Wake Forest University Health Sciences200
已完成
2 期
Bisphosphonate Treatment of Osteogenesis ImperfectaOsteogenesis ImperfectaNCT00063479Novartis Pharmaceuticals158
已完成
4 期
Bisphosphonate Therapy for Osteogenesis ImperfectaPaget Disease of BoneOsteoporosisOsteogenesis ImperfectaNCT00159419Indiana University School of Medicine18